Abstracts tagged "axial spondyloarthritis"

Abstract Number: 713 • 2015 ACR/ARHP Annual Meeting
Clinical and Imaging Efficacy of Etanercept in Early Non-Radiographic Axial Spondyloarthritis: 104-Week Treatment Results
Maxime Dougados¹, Désirée van der Heijde², Joachim Sieper³, Juergen Braun⁴, Gustavo Citera⁵, Filip van Den Bosch^6,7, Ronald Pedersen⁸, Randi Bonin⁹, Heather Jones¹⁰, Lisa Marshall¹⁰, Sameer Kotak¹¹, Isabelle Logeart¹², Bonnie Vlahos¹³, Jack F Bukowski⁹ and Walter Maksymowych¹⁴, ¹Rheumatology Department, Hôpital Cochin, Paris, France, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Medical Department I, Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Rheumatology, Consultorios Reumatológicos Pampa, Buenos Aires, Argentina, ⁶Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁷Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁸Department of Biostatistics, Pfizer, Collegeville, PA, ⁹Clinical Affairs, Pfizer, Collegeville, PA, ¹⁰Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, ¹¹Global Health and Value, Pfizer, New York, NY, ¹²Medical Affairs, Pfizer, France, Paris, France, ¹³GIPB - Clinical Sciences, Pfizer, Collegeville, PA, ¹⁴Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: In the multiphase, randomized, placebo (PBO)-controlled EMBARK study (ClinicalTrials.gov identifier: NCT01258738), clinical signs/symptoms and MRI-measured inflammation were evaluated in patients with early, active non-radiographic…
Abstract Number: 714 • 2015 ACR/ARHP Annual Meeting
Baseline MRI and CRP As Predictors of Response to Etanercept in the Management of Patients with Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Matthew A. Brown¹, Paul A. Bird², Philip C. Robinson³, Philip J. Mease⁴, Filip van Den Bosch⁵, Christine Surian⁶, Zirke Wiid⁶, Heather Jones⁷, Annette Szumski⁸ and Lisa Marshall⁷, ¹Translational Research Institute, University of Queensland Diamantina Institute, Brisbane, Australia, ²University of New South Wales, Sydney, Australia, ³University of Queensland & Royal Brisbane and Women's Hospital, Brisbane, Australia, ⁴Rheumatology Research, Swedish Medical Center, Seattle, WA, ⁵Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁶Pfizer Australia, Sydney, Australia, ⁷Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, ⁸Department of Biostatistics, Pfizer, Collegeville, PA
Background/Purpose: Treatment with tumor necrosis factor α (TNFα) inhibitors has been shown to be effective in improving disease activity and functional capacity in patients with…
Abstract Number: 976 • 2015 ACR/ARHP Annual Meeting
The Reason of Discontinuation of a First TNF Inhibitor Affects Drug Retention of a Second Anti-TNF Agent in Axial Spondyloarthritis
Adrian Ciurea¹, Pascale Exer², Ulrich Weber^3,4, Giorgio Tamborrini⁵, Beate Steininger¹, Rudolf O. Kissling⁶, Jürg Bernhard⁷ and Almut Scherer⁸, ¹Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Private rheumatology practice, Basel, Switzerland, ³Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark, ⁴Department of Research, King Christian 10th Hospital for Rheumatic Diseases, Graasten, Denmark, ⁵Department of Rheumatology, University Hospital, Zurich, Switzerland, ⁶Division of Rheumatology, Balgrist University Hospital, Zurich, Switzerland, ⁷Rheumatology and Rehabilitation, Bürgerspital Solothurn, Solothurn, Switzerland, ⁸SCQM Foundation, Zurich, Switzerland
Background/Purpose: Conflicting results have been demonstrated in axial spondyloarthritis (axSpA) with regard to whether effectiveness of a second (2°) TNFi depends on the reason of…
Abstract Number: 1231 • 2015 ACR/ARHP Annual Meeting
The Prevalence of Non-Radiographic Axial Spondyloarthritis Among Patients with Inflammatory Back Pain in Rheumatology Practices
Rubén Burgos-Vargas¹, James Wei², Mahboob U Rahman³, Nurullah Akkoc⁴, Syed A. Haq⁵, Mohammed Hammoudeh⁶, Ehab Mahgoub⁷, Ena Singh⁸, Lyndon Llamado⁹, Khalid Shirazy¹⁰, Sameer Kotak¹¹, Connie Hammond⁷, Ronald Pedersen¹², Qi Shen¹³ and Bonnie Vlahos¹³, ¹Rheumatology, Hospital General de Mexico, Mexico city, Mexico, ²Division of Allergy, Immunology and Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan, ³Perelman School of Medicine, University of Pennsylvania, Philadephia, PA, ⁴Department of Rheumatology, Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey, ⁵Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, ⁶Medicine, Hamad Medical Corporation, Doha, Qatar, ⁷Pfizer, Collegeville, PA, ⁸500 Arcola Road, Pfizer, Collegeville, PA, ⁹Pfizer, Makati, Philippines, ¹⁰Pfizer, Dubai, United Arab Emirates, ¹¹Global Health and Value, Pfizer, New York, NY, ¹²Department of Biostatistics, Pfizer, Collegeville, PA, ¹³GIPB - Clinical Sciences, Pfizer, Collegeville, PA
Background/Purpose: The diagnosis of Ankylosing Spondylitis (AS) is delayed by >10 years after the symptoms develop, as by definition the modified NY criteria for classification…
Abstract Number: 1283 • 2015 ACR/ARHP Annual Meeting
The Burden of Non-Radiographic Axial Spondyloarthritis from the Employer Perspective: A Real World European Study
Tim Holbrook¹, Robert Wood¹, Christopher Black², Xiaohan Hu² and Sumesh Kachroo², ¹Adelphi Real World, Macclesfield, United Kingdom, ²CORE, Merck & Co., Inc., Rahway, NJ
Background/Purpose: Non-radiographic axial spondyloarthritis (nr-axSpA) is a burdensome disease to both the patient and the healthcare system, as previous research has indicated. However, the societal…
Abstract Number: 1284 • 2015 ACR/ARHP Annual Meeting
Burden of Illness Associated with Non-Radiographic Axial Spondyloarthritis: A European Real World Database Analysis from the Clinical and Healthcare System Perspective
Tim Holbrook¹, Robert Wood¹, Christopher Black², Xiaohan Hu² and Sumesh Kachroo², ¹Adelphi Real World, Macclesfield, United Kingdom, ²CORE, Merck & Co., Inc., Rahway, NJ
Background/Purpose: Whilst the burden of axial spondyloarthritis (axSpA) is well known, non-radiographic (nr)-axSpa has only recently been identified as a distinct spondyloarthritic indication with its…
Abstract Number: 2025 • 2015 ACR/ARHP Annual Meeting
Modification of Structural Lesions on Magnetic Resonance Imaging By Etanercept: A 12-Week Randomized Placebo-Controlled Trial
Walter Maksymowych¹, Stephanie Wichuk², Maxime Dougados³, Heather Jones⁴, Annette Szumski⁵, Lisa Marshall⁴, Jack F Bukowski⁶ and Robert G Lambert⁷, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Rheumatology Research Lab, University of Alberta, Edmonton, AB, Canada, ³Rheumatology Department, Hôpital Cochin, Paris, France, ⁴Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, ⁵Department of Biostatistics, Pfizer, Collegeville, PA, ⁶Clinical Affairs, Pfizer, Collegeville, PA, ⁷Department of Radiology & Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Modification of structural lesions by anti-TNF therapy has not been demonstrated in a randomized placebo (PBO)-controlled trial. The Spondyloarthritis Research Consortium of Canada (SPARCC)…
Abstract Number: 2298 • 2015 ACR/ARHP Annual Meeting
Misdiagnosis of Fibromyalgia (FM) As Axial Spondylarthritis (SpA): Lessons from Analysis of 26 Cases
Dongfeng Liang, Jianglin Zhang and Feng Huang, Rheumatology, Chinese PLA General Hospital, Beijing, China
Background/Purpose: Both patients with fibromyalgia (FM) and with axial spondyloarthritis (SpA) are suffering from pain. The patients with axial SpA are mainly manifested as inflammatory…
Abstract Number: 2324 • 2014 ACR/ARHP Annual Meeting
Only 30% Rheumatologists Collect Basdai in Patients with Axial Spa in Daily Practice: The Potential Role of a Consensual Meeting to Improve It
Hélène Che^1,2, Adrien Etcheto^2,3, Emmanuelle Dernis Labous^4,5, Henri Nataf⁵, Patrick Boumier⁵, Philippe Breuillard⁵, Marianne Durandin-Truffinet⁵, Jacques Fechtenbaum^2,5, Veronique Gaud-Listrat^2,5, Bernard Giraud⁵, Christophe Hudry^2,5, Sylvain La Batide Alanore⁵, Patricia Le Devic⁵, Patrick Le Goux⁵, Agnes Lebrun^2,5, Emmanuel Maheu⁵, Bertrand Moura⁵, Minh Nguyen^2,5, Antoinette Sacchi⁵, Xavier Ayral^5,6, Anne Blanchais^2,5, Severine Neveu^2,5, Maxime Dougados^2,5,7 and Anna Molto^2,5,7, ¹Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, ²Université Paris René Descartes and Hôpital Cochin, Paris, France, ³Cochin Hospital, Paris Descartes University, Paris, France, ⁴Rhumatologie, Ch Du Mans, Le Mans, France, ⁵Réseau Hôpital et Ville en Rhumatologie (RHEVER) Network, Paris, France, ⁶Université Paris René Descartes and Hôpital Cochin, paris, France, ⁷INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France
Background/Purpose The current recommendations for optimal monitoring of axial spondyloarthritis (SpA) are to assess regularly disease activity. The two proposed tools comprise clinical aspects as…
Abstract Number: 544 • 2014 ACR/ARHP Annual Meeting
Observed Incidence Rates of Uveitis over 96 Weeks of Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis
James T. Rosenbaum^1,2, Martin Rudwaleit³, Robert B. M. Landewé⁴, Helena Marzo-Ortega^5,6, Joachim Sieper⁷, Désirée M. van der Heijde⁸, Owen Davies⁹, Christian Stach¹⁰, Tommi Nurminen¹⁰ and Atul A. Deodhar¹¹, ¹OHSU, Portland, OR, ²Arthritis and Rheumatic diseases, Oregon Health and Science University, Portland, OR, ³Endokrinologikum, Berlin, Germany, ⁴Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁵Leeds Teaching Hospitals NHS Trust and NIHR Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁶University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁷Rheumatology Department,, University Hospital Charité, Berlin, Germany, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Monheim, Germany, ¹¹Oregon Health and Sciences University, Portland, OR
Background/Purpose: Axial spondyloarthritis (axSpA) is characterized by inflammation in the spine and sacroiliac joints, but can also manifest as inflammation at extra-spinal sites, most commonly…
Abstract Number: 2302 • 2014 ACR/ARHP Annual Meeting
Classification of Juvenile Spondyloarthropathies According to ASAS Criteria
Marìa M. Katsicas¹ and Ricardo A. G. Russo², ¹Immunology & Rheumatology., Hospital de Pediatrìa Garrahan, Buenos Aires, Argentina, ²Immunology & Rheumatology, Hospital de Pediatria Garrahan, Buenos Aires, Argentina
Background/Purpose The juvenile spondyloarthropathies (JSpA) are a group of related seronegative rheumatic diseases characterized by involvement of the axial , peripheral large joints and entheses.…
Abstract Number: 543 • 2014 ACR/ARHP Annual Meeting
Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol
Désirée M. van der Heijde¹, Atul A. Deodhar², Owen Davies³, Tommi Nurminen⁴ and Martin Rudwaleit⁵, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Arthritis and Rheumatic diseases, Oregon Health and Science University, Portland, OR, ³UCB Pharma, Slough, United Kingdom, ⁴UCB Pharma, Monheim, Germany, ⁵Endokrinologikum, Berlin, Germany
Background/Purpose: Early response to anti-TNF therapy has been shown to be a strong predictor of good long-term outcomes in ankylosing spondylitis (AS).1 However, early identification…
Abstract Number: 1895 • 2014 ACR/ARHP Annual Meeting
Sacroiliitis at Diagnosis in Children with Juvenile Spondyloarthritis
Pamela Weiss¹, Rui Xiao^2,3 and Nancy Chauvin⁴, ¹Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ²Department of Pediatrics, Division of Biostatistics, Children's Hospital of Philadelphia, Philadelphia, PA, ³Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ⁴Radiology, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose The prevalence of sacroiliitis in children with juvenile spondyloarthritis (JSpA) at diagnosis is unknown. We aimed to evaluate: 1) the prevalence of sacroiliitis at…
Abstract Number: 1893 • 2014 ACR/ARHP Annual Meeting
Substantial Structural Lesions on MRI in the Sacroiliac Joints of Patients with Non-Radiographic Axial Spondyloarthritis Even in the Absence of MRI Inflammation
Walter P. Maksymowych¹, S Wichuk¹, H Jones², A Szumski³, L Marshall⁴, J Bukowski⁵ and RG Lambert⁶, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Inflammation & Immunology, Pfizer Inc., Collegeville, PA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Inflammation Immunology Disease Group, Pfizer Inc., Collegeville, PA, ⁵Pfizer Inc., Collegeville, PA, ⁶Radiology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Treatment of axial SpA is increasingly aimed at intervention early in the disease course before radiographic sacroiliitis has appeared and when response to treatment…
Abstract Number: 1573 • 2014 ACR/ARHP Annual Meeting
Norwegian Psoriatic Arthritis Patients Are More Obese Than Rheumatoid Arthritis and Axial Spondyloarthropathy Patients
Brigitte Michelsen¹, Andreas P. Diamantopoulos², Arthur Kavanaugh³ and Glenn Haugeberg^1,4, ¹Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Department of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ³University of California San Diego, La Jolla, CA, ⁴Faculty of Health and Sport Sciences, University of Agder, Kristiansand, Norway
Background/Purpose Higher rates of obesity in psoriatic arthritis (PsA) compared to rheumatoid arthritis (RA) have been described. Obesity, C-reactive protein (CRP) and inflammatory arthritides itself…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].